ProBioGen has closed a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of their lead antibody candidate.

ProBioGen's CHO.RiGHT cell line development including their latest DirectedLuck transposase and platform processes enable the development to provide a high-expressing stable cell line and a robust manufacturing process. Further, ProBioGen's proprietary cell culture medium makes manufacturing processes even more robust, with improved protein titers and cell growth behavior. The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.

"We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard to treat cancers. We are thrilled to support them with our expertise and technology to move this candidate towards the clinic", says Dr. Gabriele Schneider, Chief Business Offer.